A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Conditions

Soft Tissue

Phase III

What is the purpose of this trial?

This study evaluates nirogacestat in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). Half of the participants will receive nirogacestat while the other half will receive placebo.

  • Trial with
    SpringWorks Therapeutics
  • Start Date
    06/09/2019
  • End Date
    10/30/2020

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Matthew Piscatelli

  • Last Updated
    06/12/2019
  • Study HIC
    #2000024102